HLB Pharmaceutical Co., Ltd. (047920) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for HLB Pharmaceutical Co., Ltd. (047920:KRX), powered by AI.

Current Price
₩9,020
P/E Ratio
64.0
Market Cap
295.9B
Sector
Healthcare
What is the HLB Pharmaceutical Co., Ltd. stock price forecast?

HLB Pharmaceutical Co., Ltd. is currently trading at ₩9,020. View real-time AI analysis on Alpha Lenz.

What is HLB Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for HLB Pharmaceutical Co., Ltd. on Alpha Lenz.

What is HLB Pharmaceutical Co., Ltd.'s P/E ratio?

HLB Pharmaceutical Co., Ltd.'s P/E ratio is 64.0.

HLB Pharmaceutical Co., Ltd.

KRX · 047920
₩9,020+950(+11.77%)Market closedKRX regular session 09:00–15:30 KST
Ask about HLB Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

HLB Pharmaceutical Co., Ltd. trades at a P/E of 64.0 (premium valuation) with modest ROE of 3.8%. 3Y revenue CAGR of 24.1% highlights clear growth momentum.

Ask for details

Company Overview

HLB Pharmaceutical Co., Ltd. is a comprehensive entity in the pharmaceuticals sector, primarily focused on the research, development, and distribution of pharmaceutical products. This company plays a vital role in advancing healthcare by delivering a range of medical solutions that span various therapeutic areas. HLB Pharmaceutical is recognized for its commitment to innovation in drug discovery and biopharmaceuticals. With a strategic emphasis on both domestic and international markets, the company impacts numerous sectors, including biotechnology, healthcare services, and medical technology. Its operations involve intricate processes of clinical trials, regulatory compliance, and manufacturing excellence. Positioned as a key player within the pharmaceutical market, HLB Pharmaceutical Co., Ltd. contributes to the globalization of healthcare, catering to an array of health needs across different demographics. The firm's ongoing projects and partnerships make it a significant entity in the pursuit of medical advancements, especially in emerging markets where healthcare demand is rapidly increasing.

CEO박재형
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩295,850,191,120Market Cap
₩205,581,738,650Revenue
32.80MShares Out
0Employees

Margins

51.81%Gross
4.71%EBITDA
0.52%Operating
2.43%Pre-Tax
2.22%Net

Valuation

63.97P/E
2.34P/B
1.42EV/Sales
31.56EV/EBITDA
-44.04P/FCF

Growth (CAGR)

24.13%Rev 3Yr
38.34%Rev 5Yr
N/AOp Inc 3Yr
0.32%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

2.78%ROA
3.79%ROE
3.48%ROIC

Financial Health

₩7,608,680,970Cash & Cash Equivalents
₩37,924,947,630Net Debt
36.38%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

HLB Pharmaceutical Co., Ltd. (ticker: 047920) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $295.9B.

The current price is ₩9,020 with a P/E ratio of 63.97x and P/B of 2.34x.

ROE is 3.79% and operating margin is 0.52%. Annual revenue is $205.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
HLB Pharmaceutical Co., Ltd. (047920) Stock Forecast 2026 ₩9,020 — Price, Financials & Analyst Targets | Alpha Lenz